Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,458.80
(
-1.10%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.44
(
3.84%
)
Bitcoin
70,404.35
(
0.72%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 212416

Friday, 07/14/2017 4:36:06 PM

Friday, July 14, 2017 4:36:06 PM

Post# of 257264

MNTA—Do you know the hold up with M254?

I don't think there is a holdup per se. Rather, MNTA prioritized M230 due to the partnership with CSL (announced in Jan 2017, but clearly in the works during 2016) and M281, which Craig Wheeler considers MNTA's most promising new-drug candidate.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today